Oramed CSO Kidron donates 86,166 shares

Oramed Pharmaceuticals director and Chief Scientific Officer Miriam Kidron reported a charitable donation of company stock.

Rhea-AI Filing Summary

Oramed Pharmaceuticals director and Chief Scientific Officer Miriam Kidron reported a charitable donation of company stock. On 01/14/2026, she gifted 86,166 shares of Oramed Pharmaceuticals Inc. common stock in a transaction coded "G," which is designated for gifts. The filing states this was a charitable donation, not a market trade, so no price was reported and no value was received for the shares.

After the donation, Kidron beneficially owned 1,343,498 shares of Oramed common stock in direct ownership form. The footnote adds that she is not affiliated with, and has no control over, the recipient organization.

Insider Trade Summary

86,166 shares gifted

Gift 1 txn

Insider Kidron Miriam

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	86,166	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,343,498 shares (Direct)

Footnotes (1)

1. F1. This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORMP's Miriam Kidron report?

Miriam Kidron, a director and Chief Scientific Officer of Oramed Pharmaceuticals Inc. (ORMP), reported a charitable donation of 86,166 shares of the company’s common stock on 01/14/2026.

Was Miriam Kidron’s ORMP stock donation a market transaction?

No. The filing explains that the 86,166-share transaction was a charitable donation and "is not a market transaction," so no price was reported and no value was received.

How many ORMP shares does Miriam Kidron hold after the reported donation?

Following the donation, Miriam Kidron beneficially owned 1,343,498 shares of Oramed Pharmaceuticals Inc. common stock in direct ownership.

What is Miriam Kidron’s role at Oramed Pharmaceuticals (ORMP)?

Miriam Kidron is both a director and an officer of Oramed Pharmaceuticals Inc., serving as the company’s Chief Scientific Officer.

Is Miriam Kidron affiliated with the charity that received the ORMP shares?

According to the footnote, the reporting person "is not affiliated with, and has no control over, the donee" that received the 86,166 donated shares.

What transaction code was used for Miriam Kidron’s ORMP stock donation?

The transaction used code "G", which in Form 4 reporting denotes a gift of securities, consistent with the description of a charitable donation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kidron Miriam

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS, THIRD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		G(1)		86,166	D	$0	1,343,498	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee.

	/s/ Miriam Kidron	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.